Overview of Guarantees
To meet the funding needs for daily operations and business development of the company and its subsidiaries, and to ensure smooth applications for comprehensive bank credit (including but not limited to RMB or foreign currency loans, project loans, trade financing, bank acceptance bills, letters of credit, guarantees, bill discounting, factoring, export financing, foreign exchange forward transactions, and related derivative products), the company forecasts that in 2026, it will provide external guarantees not exceeding RMB 6.6 billion (including equivalent foreign currency). The guarantees will include:
- Guarantees provided by the company for its subsidiaries within the consolidated financial statements.
- Mutual guarantees among subsidiaries within the consolidated financial statements, with a total guarantee limit of RMB 5.9 billion for wholly-owned subsidiaries and RMB 700 million for controlling subsidiaries with a debt-to-asset ratio of less than 70%. Guarantees that are still in effect as of the date of the 2025 annual general meeting will not be included in the aforementioned estimated guarantee limit for 2026. The methods of guarantees include but are not limited to guarantees, mortgages, and pledges. The company may adjust the guarantee limits among eligible guarantee objects (including newly added subsidiaries in the future) within the above-mentioned guarantee limit based on actual conditions.
| Guarantee Provider | Guaranteed Party | Shareholding Ratio | Latest Debt-to-Asset Ratio as of December 31, 2025 | Guarantee Balance | New Guarantee Limit | Guarantee Limit as a Percentage of Latest Net Assets | Related Guarantee |
|---|---|---|---|---|---|---|---|
| 康龙化成（绍兴）药业有限公司 | 康龙化成（绍兴）药业有限公司 | 100% | 36.38% | 0.00 | 6 | 3.98% | No |
| 康龙化成（宁波）药物开发有限公司 | 康龙化成（宁波）药物开发有限公司 | 100% | 52.03% | 3.59 | 1 | 0.66% | No |
| Pharmaron (Hong Kong) International Limited | Pharmaron (Hong Kong) International Limited | 100% | 56.29% | 39.20 | 49 | 32.53% | No |
| 康龙化成（西安）科技发展有限公司 | 康龙化成（西安）科技发展有限公司 | 100% | 68.38% | 2.24 | 0 | 0.00% | No |
| 康龙化成（北京）医药科技有限公司 | 康龙化成（北京）医药科技有限公司 | 100% | 73.32% | 5.61 | 3 | 1.99% | No |
| 康龙化成（宁波）生物医药有限公司 | 康龙化成（宁波）生物医药有限公司 | 88.89% | 29.37% | 0.00 | 4 | 2.66% | No |
| 康龙化成（成都）临床研究服务有限公司 | 康龙化成（成都）临床研究服务有限公司 | 82.33% | 51.25% | 1.53 | 3 | 1.99% | No |
| Total | - | - | - | 52.17 | 66 | 43.81% | - |
The company and its subsidiaries will adhere to prudent principles when conducting external guarantees and will strictly follow the relevant laws, regulations, and institutional documents for the approval of external guarantee matters. This proposal for the estimated external guarantee limit will be valid from the date of approval at the 2025 annual general meeting until the date of the 2026 annual general meeting. The above guarantee limit can be reused within the validity period. The board of directors requests the shareholders' meeting to authorize the chairman of the company and his authorized representatives to sign relevant contracts for the above guarantee matters. This estimated guarantee limit still needs to be submitted for approval by the shareholders' meeting and does not involve related transactions. For guarantees exceeding the total amount mentioned above, the company will follow the specific provisions of the Company Law, the Shenzhen Stock Exchange GEM Listing Rules, the Shenzhen Stock Exchange Self-Regulatory Guidelines No. 2 for GEM Listed Companies, and the Articles of Association to fulfill the corresponding review procedures.
Basic Information of Guaranteed Parties
- 康龙化成（绍兴）药业有限公司
- Unified Social Credit Code: 91330604MA2894X91L
- Established Date: January 3, 2017
- Address: No. 18, East Jingqi Road, Shangyu District, Shaoxing City, Zhejiang Province
- Registered Capital: RMB 1,500,000,000
- Legal Representative: Zhang Faliang
- Business Scope: Drug production; veterinary drug production; import of new chemical substances; entrusted drug production; hazardous waste management; production of new chemical substances; import and export of drugs (projects subject to approval must be conducted after approval by relevant departments).